Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure at Different Disease Stages

Table 2

Baseline demographic and clinical characteristics of all participants.

	NC ()	CHB ()	ACLF-E ()	ACLF-M ()	ACLF-L ()
Age (mean (SD), years)
Sex (male/female)	16/4	17/3	18/2	17/3	16/4
Virus infection time
<10 years	N.D	4	0	3	1
≥10 years	N.D	16	20	17	19
HBeAg (+/−)	N.D	9/11	6/14	7/13	4/16
HBV-DNA (×10^7IU/mL)	N.D
WBC (×10^9/L)
LYM (%)
ALB (g/L)
ALT (IU/L)
AST (IU/L)
TBil (μmol/L)
PT (S)	N.D
INR	N.D
MELD score	N.D	N.D

Data are presented as numbers (%) or , unless otherwise indicated. NC: normal control; CHB: chronic hepatitis B; ACLF-E: early-stage ACLF; ACLF-M: mid-stage ACLF; ACLF-L: late-stage ACLF; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; WBC: white blood cell; LYM: lymphocyte; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate minotransferase; TBil: total bilirubin; PT: prothrombin time; INR: international normalized ratio; MELD score: Model for End-Stage Liver Disease score; ACLF: acute-on-chronic liver failure; N.D.: not determined.